{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T10:33:31Z","timestamp":1781951611912,"version":"3.54.5"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2019,1,12]],"date-time":"2019-01-12T00:00:00Z","timestamp":1547251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>This study aimed to estimate the rate of cardiovascular (CV) events in the real world in patients at high risk of recurrent CV events similar to the FOURIER trial population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>A retrospective population-based cohort study was conducted using Swedish national registers from 1 July 2001 to 31 December 2015. Patients in the atherosclerotic cardiovascular disease (ASCVD) prevalent cohort met the FOURIER-like inclusion criteria, including treatment with high\/moderate-intensity statins, on 1 July 2006. Additionally, two cohorts defined by diagnosis of incident ischaemic stroke (IS) and incident myocardial infarction (MI), meeting the FOURIER-like inclusion criteria were followed from date of diagnosis. Event rates were calculated for the hard major adverse cardiovascular events (MACE) composite: MI, IS, and CV death; and the ASCVD composite: MI, IS, unstable angina, coronary revascularization, and CV death. Approximately half of patients experienced a CV event (ASCVD composite) during follow-up. The MACE composite rates\/100 person-years were 6.3, 11.9, and 12.3 in the ASCVD prevalent (n\u2009=\u200954\u00a0992), MI incident (n\u2009=\u200945\u00a0895), and IS incident (n\u2009=\u200936\u00a0134) cohorts, respectively. The ASCVD composite rates\/100 person-years were 7.0, 21.7, and 12.9 in the ASCVD prevalent, MI incident, and IS incident cohorts, respectively. The multiple-event MACE composite rates\/100 person-years were 8.5 (ASCVD prevalent cohort), 15.4 (MI incident cohort), and 14.4 (IS incident cohort).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this real-world setting, CV event rates were high in all studied cohorts. In particular, the MACE composite rates were two to three times higher than in the FOURIER clinical trial, indicating a substantial disease burden despite treatment with moderate or high-intensity statins.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjqcco\/qcy058","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T10:59:29Z","timestamp":1546945169000},"page":"225-232","source":"Crossref","is-referenced-by-count":40,"title":["Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data"],"prefix":"10.1093","volume":"5","author":[{"given":"Maria","family":"Lindh","sequence":"first","affiliation":[{"name":"Quantify Research, Hantverkargatan 8, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Banefelt","sequence":"additional","affiliation":[{"name":"Quantify Research, Hantverkargatan 8, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M","family":"Fox","sequence":"additional","affiliation":[{"name":"Strategic Healthcare Solutions LLC, 133 Cottonwood Creek Lane, Aiken, SC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hallberg","sequence":"additional","affiliation":[{"name":"Quantify Research, Hantverkargatan 8, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hui","family":"Tai","sequence":"additional","affiliation":[{"name":"Department of Global Health Economics, One Amgen center dr. Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Eriksson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet, Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Villa","sequence":"additional","affiliation":[{"name":"Department of Global Health Economics, AMGEN Europe GmbH, Suurstoffi 22, Rotkreuz, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria K","family":"Svensson","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Global Health Economics, One Amgen center dr. Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,1,12]]},"reference":[{"key":"2019070811253821200_qcy058-B1","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.21037\/cdt.2017.03.06","article-title":"Global progress in prevention of cardiovascular disease","volume":"7","author":"Mendis","year":"2017","journal-title":"Cardiovasc Diagn Ther"},{"key":"2019070811253821200_qcy058-B2","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1093\/eurheartj\/ehw334","article-title":"Cardiovascular disease in Europe: epidemiological update 2016","volume":"37","author":"Townsend","year":"2016","journal-title":"Eur Heart J"},{"key":"2019070811253821200_qcy058-B3","year":"2017"},{"key":"2019070811253821200_qcy058-B4","volume-title":"Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health","author":"Fuster","year":"2010"},{"key":"2019070811253821200_qcy058-B5","author":"Bloom","year":"2011"},{"key":"2019070811253821200_qcy058-B6","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"2019070811253821200_qcy058-B7","first-page":"S1","author":"Stone","year":"2013"},{"key":"2019070811253821200_qcy058-B8","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"2019070811253821200_qcy058-B9","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"2019070811253821200_qcy058-B10","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"2019070811253821200_qcy058-B11","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"2019070811253821200_qcy058-B12","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"2019070811253821200_qcy058-B13","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"2019070811253821200_qcy058-B14","year":"2007"},{"key":"2019070811253821200_qcy058-B15","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1093\/eurheartj\/ehn362","article-title":"Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial","volume":"29","author":"Murphy","year":"2008","journal-title":"Eur Heart J"},{"key":"2019070811253821200_qcy058-B16","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1016\/j.jacc.2009.10.005","article-title":"Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial","volume":"54","author":"Murphy","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2019070811253821200_qcy058-B17","doi-asserted-by":"crossref","first-page":"82.","DOI":"10.4103\/2229-516X.157148","article-title":"Real world data: additional source for making clinical decisions","volume":"5","author":"Mahajan","year":"2015","journal-title":"Int J Appl Basic Med Res"},{"key":"2019070811253821200_qcy058-B18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.pmedr.2017.03.001","article-title":"Risk of mortality and recurrent cardiovascular events in patients with acute coronary syndromes on high intensity statin treatment","volume":"6","author":"Rockberg","year":"2017","journal-title":"Prev Med Rep"},{"key":"2019070811253821200_qcy058-B19","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2019070811253821200_qcy058-B20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10654-016-0117-y","article-title":"Registers of the Swedish total population and their use in medical research","volume":"31","author":"Ludvigsson","year":"2016","journal-title":"Eur J Epidemiol"},{"key":"2019070811253821200_qcy058-B21","doi-asserted-by":"crossref","first-page":"450.","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"2019070811253821200_qcy058-B22","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bcpt.12613","article-title":"The first decade with the Swedish prescribed drug register\u2013a systematic review of the output in the scientific literature","volume":"119","author":"Wallerstedt","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2019070811253821200_qcy058-B23","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish Prescribed Drug Register\u2014opportunities for pharmacoepidemiological research and experience from the first six months","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2019070811253821200_qcy058-B24","volume-title":"Drug Class Review: HMG-CoA Reductase Inhibitors (Statins) and Fixed-Dose Combination Products Containing a Statin: Final Report Update 5","author":"Smith","year":"2009"},{"key":"2019070811253821200_qcy058-B25","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"2019070811253821200_qcy058-B26","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/13696998.2017.1284078","article-title":"Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context","volume":"20","author":"Toth","year":"2017","journal-title":"J Med Econ"},{"key":"2019070811253821200_qcy058-B27","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/clc.22428","article-title":"Burden of first and recurrent cardiovascular events among patients with hyperlipidemia","volume":"38","author":"Punekar","year":"2015","journal-title":"Clin Cardiol"},{"key":"2019070811253821200_qcy058-B28","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/jamacardio.2017.2762","article-title":"Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease","volume":"2","author":"Fonarow","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2019070811253821200_qcy058-B29","first-page":"20","volume-title":"Information from the Swedish Medical Products Agency","year":"2014"},{"key":"2019070811253821200_qcy058-B30","article-title":"Statiner f\u00f6r kardiovaskul\u00e4r prevention hos h\u00f6griskpatienter med ordin\u00e4ra till m\u00e5ttligt f\u00f6rh\u00f6jda lipidniv\u00e5er","year":"2016","journal-title":"Janusinfo"},{"key":"2019070811253821200_qcy058-B31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.atherosclerosis.2016.01.018","article-title":"Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries\u2014findings from the EUROASPIRE IV survey","volume":"246","author":"Reiner","year":"2016","journal-title":"Atherosclerosis"},{"key":"2019070811253821200_qcy058-B32","first-page":"S0735","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","author":"Grundy","year":"2018","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal - Quality of Care and Clinical Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjqcco\/article-pdf\/5\/3\/225\/28916605\/qcy058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T11:26:24Z","timestamp":1562585184000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article\/5\/3\/225\/5288508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,12]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,1,12]]},"published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjqcco\/qcy058","relation":{},"ISSN":["2058-5225","2058-1742"],"issn-type":[{"value":"2058-5225","type":"print"},{"value":"2058-1742","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2019,1,12]]}}}